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ADRB1 Variants
n Atrial Fibrillation
Small Steps and Giant Leaps
Toward Personalized Therapy
in Cardiovascular Disease*
Sharon Cresci, MD
St. Louis, Missouri
Atrial fibrillation is the most common cardiac arrhythmia,
affecting about 3 million adults in the United States and
costing over 26 million dollars annually to treat (1,2). As a
common cause of symptoms and precipitant of decompen-
sated heart failure, atrial fibrillation contributes greatly to
cardiovascular morbidity and disability. Many of the symp-
toms and adverse outcomes associated with untreated atrial
fibrillation may be attributed to the typically rapid ventric-
ular rate, and therefore, a cornerstone of management is rate
control. Rate control for atrial fibrillation can ameliorate
symptoms and improve outcomes, and in prospective, ran-
domized testing, shows no disadvantage compared with
rhythm control (Atrial Fibrillation Follow-Up Investigation
of RhythmManagement [AFFIRM]) (3). Nevertheless, the
pharmacological management of atrial fibrillation remains
challenging, and clinicians caring for patients with atrial
fibrillation have limited tools to help tailor and/or predict
response to medical therapy for the individual patient.
See page 49
In this issue of the Journal, Parvez et al. (4) provide
vidence that represents a significant step towards realizing
he “giant leap” of personalized medicine for individuals
ith atrial fibrillation by advancing a large body of work
ith their analysis of the association between 2 common
enetic variants in the gene encoding the 1-adrenergic
eceptor (ADRB1) and ventricular rate control in response
o treatment in patients with atrial fibrillation. Their study
ook advantage of the extensive data available in the Van-
erbilt AF Registry, a clinical and genetic registry of adult
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Cardiovascular Division, Department of Medicine, Washington Univer-n
sity School of Medicine, St. Louis, Missouri. The author reports that she has no
relationships relevant to the contents of this paper to disclose.atients with documented atrial fibrillation or atrial flutter.
wo strengths of this registry, and of the investigation by
arvez et al. (4), are the documentation of number and dose
f prescribed medications for control of atrial fibrillation
nd the availability of echocardiographic measurements at
he time of enrollment into the registry for all patients. The
nvestigators pre-specified that they would restrict their
nalyses to attempted rate control using a -blocker, cal-
cium channel blocker, or digoxin. In addition, well-defined
and specific AFFIRM study criteria provided an objective
endpoint for adequate rate control (“responders”) within 6
months from study entry.
A total of 543 Caucasian subjects were included in the
study (344 men; 199 women), with a mean age of 61.8 14
years. Fifty-four percent (n  295) of those enrolled in the
study responded to -blockers, calcium-channel blockers,
nd/or digoxin therapy within 6 months according to
FFIRM criteria (meeting 1 of 2 criteria: 1) average resting
eart rate 80 beats/min and maximum heart rate during a
-min walk 110 beats/min; or 2) average heart rate 100
eats/min on a 24-h ambulatory Holter electrocardiogram
onitor and no heart rate 110% maximum predicted
ge-adjusted exercise heart rate). Forty-six percent (n 
48) of the cohort failed to respond. Of the nonresponders,
1% had an antiarrhythmic drug added, and 12.5% received
trioventricular node ablation and pacemaker implantation.
The authors investigated the association of ADRB1
rg389Gly and ADRB1 Ser49Gly variants with response and
found that the ADRB1 Gly389Arg variant was associated
ith significant differences in response to therapy, whereas
he ADRB1 Ser49Gly variant was not. The authors found
hat 60% of individuals with at least 1 ADRB1 389Gly allele
ere responders compared with 51% of ADRB1 Arg389Arg
omozygote individuals (p  0.04). Although the authors
ound no difference in response according to ADRB1
er49Gly genotype alone (52% vs. 55%; p  0.45), when
ombined with ADRB1 Arg389Gly genotype, prediction of
esponse by genotype became even more robust. Two-thirds
67%) of individuals who were homozygous for ADRB1
er49Ser and carried at least 1 ADRB1 389Gly allele were
responders (compared with 50% in all other haplotype
groups; p 0.001). Importantly, in multivariable regression
analysis, although clinical variables (including echocardio-
graphic variables) failed to significantly predict adequate
response to rate-control therapy, individuals carrying the
ADRB1 389Gly allele were 40% more likely to respond
(odds ratio [OR]: 1.44, 95% confidence interval [CI]: 1.01
to 2.04, p  0.05). This association persisted after adjust-
ment for age and gender (OR: 1.42, 95% CI: 1.00 to 2.03,
p  0.05).
The authors also determined the final total number and
dose of -blockers, calcium-channel blockers, or digoxin
herapy needed to achieve ventricular rate control in the
esponder group according to haplotype. Although the
umber of medication prescriptions did not differ between
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viduals who were homozygous for both alleles (ADRB1
Arg389Arg-Ser49Ser) required the highest doses, and indi-
viduals who were ADRB1 Ser49Ser homozygotes and car-
ried at least 1 ADRB1 389Gly allele required the lowest
doses (atenolol 92 mg vs. 68 mg; carvedilol 44 mg vs. 20 mg;
metoprolol 80 mg vs. 72 mg; diltiazem 212 mg vs. 180 mg;
and verapamil 276 mg vs. 200 mg, respectively; p 0.01 for
all comparisons).
ADRB1 and ADRB2 variants are perhaps the most widely
investigated genetic variants in cardiovascular disease to
date. The 1-adrenergic receptor is a G-protein–coupled
receptor and is the predominant -adrenergic receptor
ubtype expressed in cardiac tissue, mediating the response
o sympathetic stimulation. ADRB1 was cloned in 1987 and
ubsequently mapped to chromosome 10q25.3. The gene
as no introns, consists of 1,714 base pairs, and codes for a
1.3-kDa protein consisting of 477 amino acids. The ADRB1
rg389Gly and ADRB1 Ser49Gly variants are the most
common and well-studied ADRB1 variants; both are coding
ariants that cause a functional change in the encoded
rotein. The ADRB1 Arg389Gly variant is located in the
-protein binding domain and changes G-protein coupling
nd adenylyl cyclase activity. The ADRB1 Ser49Gly poly-
orphism alters agonist-promoted desensitization.
These ADRB1 variants have been previously associated
ith risk and outcomes in cardiovascular diseases such as
ypertension (5) and heart failure (6,7), and with response to
-blocker (8–13) and -agonist therapy (14,15). With respect
to atrial fibrillation, ADRB1 49Gly allele carriers (16) and
ndividuals with the ADRB1Arg389Gly-Ser49Gly haplotype
17) have been reported to have an increased risk of atrial
brillation; individuals with the ADRB1 Arg389Arg geno-
ype have been reported to have higher heart rates during
trial fibrillation and to have the highest cardioversion
esponse rate to flecanide treatment (17). Interestingly,
eveloping autoantibodies to the 1-adrenergic receptor has
also been reported to increase an individual’s risk of devel-
oping atrial fibrillation (18).
The study by Parvez et al. (4) significantly extends these
previous findings. Although prospective validation in atrial
fibrillation cohorts is needed, and some caution should be
applied to the findings because drug prescription is not
synonymous with drug compliance (19–21), if validated, the
study by Parvez et al. (4) represents a major step forward for
cardiovascular electrophysiology pharmacogenomics and
has the promise of translation to clinical practice. The
authors have elegantly demonstrated that if a (Caucasian)
individual with atrial fibrillation is ADRB1 Ser49Ser ho-
mozygous and carries at least 1 ADRB1 389Gly allele, not
only will he/she be more likely to respond to rate control
with -blocker, calcium-channel blocker, and/or digoxin,
ut he/she is also likely to require the lowest doses of these
edications to achieve this response. Thus, once identified,
hese individuals, representing more than one-third (36%)
f the population studied, are predicted to respond favor-bly. The pressing question is how to guide therapy in those
ndividuals that do not have this haplotype. In the study, these
ndividuals more frequently required treatment with either
igher doses of -blockers, calcium-channel blockers, and/or
digoxin, or, antiarrhythmic drugs and/or atrioventricular node
ablation and pacemaker implantation. Nevertheless, given how
commonly atrial fibrillation appears in practice and the high
costs associated with its care, predictive instruments incorpo-
rating genotype, as suggested by the work of Parvez et al. (4),
may have great value in tailoring the therapeutic approach to an
individual patient and deserve prospective testing. If con-
firmed, translating the observations of this report into practice
could represent a small, but significant, step toward using
genotype to realize the “giant leap” promise of personalized
therapy for all patients with cardiovascular disease.
Reprint requests and correspondence: Dr. Sharon Cresci, Car-
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